The non-smoking lung gland cancer crowd's carcinogenic gene mutation table is set up

The non-smoking lung gland cancer crowd's carcinogenic gene mutation table is set up
The non-smoking lung gland cancer crowd's carcinogenic gene mutation table is set up
It is reported ' Reporter Hu DeRong) Life biochemistry and cell research institute Ji Hong refined seminar of research institute in Shanghai of the Chinese Academy of Sciences cooperate with tumour hospital of Fudan University, have set up and improved the key carcinogenic gene mutation table in the non-smoking lung gland cancer crowd on the basis of bigger sample. The relevant scientific paper was published on " the public science library synthesized " on the magazine online a few days ago. The result of study in 52 cases of lung cancer sample in the past of Ji Hong refined seminar shows, the tumour sample of the non-smoking lung gland cancer patient's source has special carcinogenic gene mutation tables: Have one kind in EGFR, KRAS, HER2 and these 4 kinds of gene mutation of EML4-ALK in the tumour sample of about 90% of the patients. Because already some small molecule medicines can inhibit the activity of EGFR, HER2 and ALK gene mutation of mutation effectively in the clinical treatment at present, so the most persons who didn't get lung gland cancer smoking may benefit from it. Recently, the scientific research personnel of Ji HongBin seminar are in 202 tumour samples of non-smoking lung gland cancer patient's source, have merged and gone on finding to analyze with clinical relevance to EGFR, KRAS, HER2 and ALK gene mutation and ROS1 gene found recently. The result of study shows, have in the tumour sample of about 89% of the patients and only have one kind in the above-mentioned 5 kinds of gene mutation. This research work has not only verified past results of study of scientific research personnel of this seminar, and find the patient of EGFR gene mutation with comparing olderly by the patient of EGFR gene mutation, and the patient of unknown gene mutation exists to compare with patient with known mutation age is partial and small. For clinical the intersection of individual and the intersection of molecule and to treat and offer the theoretical foundation target result of study this.


|